Скачайте изображение (превью) выбрав качество

320x180 480x360 640x480 1280x720

Watch the full video on Radcliffe Cardiology here:

In this in-depth conversational interview, Late-breaker host Dr Harriette Van Spall (McMaster University, CA) meets PI, Prof Adriaan Voors (University Medical Center Groningen, NL) to discuss the EMPULSE trial. The aim of the trial was to evaluate empagliflozin compared with placebo among patients with acute decompensated heart failure.

Presented first at AHA 2021, the trial showed that that empagliflozin was beneficial at reducing adverse events among acute decompensated heart failure patients.

Recorded remotely from Groningen and Hamilton, 2021.

This content is intended for healthcare professionals only.

Radcliffe Cardiology is a dynamic, digitally-focused producer & publisher of Cardiovascular, Renal and Metabolic (CVRM) content for physicians worldwide. We aim to assist in the continuous education of physicians within the cardiology fraternity, generating a range of clinical content through collaboration with leading cardiologists from around the globe.

Чтобы скачать видео "AHA 2021 Late-Breaker Discussion: The EMPULSE Trial" передвинте ползунок вправо